Cargando…

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays

Even though it is currently well-established that α-synuclein aggregation is closely associated with the pathological events in Parkinson’s disease (PD) and several other neurodegenerative disorders, collectively called synucleinopathies, the mechanistic link between α-synuclein aggregates and the o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anagnostou, Dimitrios, Sfakianaki, Garifalia, Melachroinou, Katerina, Soutos, Miltiadis, Constantinides, Vassilios, Vaikath, Nishant, Tsantzali, Ioanna, Paraskevas, George P., Agnaf, Omar El, Vekrellis, Kostas, Emmanouilidou, Evangelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340737/ https://www.ncbi.nlm.nih.gov/pubmed/37443586 http://dx.doi.org/10.3390/diagnostics13132192

Ejemplares similares

Intrastriatal Administration of Exosome-Associated Pathological Alpha-Synuclein Is Not Sufficient by Itself to Cause Pathology Transmission
por: Karampetsou, Mantia, et al.
Publicado: (2020)

The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer’s Disease
por: Kapaki, Elisabeth, et al.
Publicado: (2013)

Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease
por: Leandrou, Emmanouela, et al.
Publicado: (2019)

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

In silico modeling of the effects of alpha-synuclein oligomerization on dopaminergic neuronal homeostasis
por: Ouzounoglou, Eleftherios, et al.
Publicado: (2014)

Assessment of α-Synuclein Secretion in Mouse and Human Brain Parenchyma
por: Emmanouilidou, Evangelia, et al.
Publicado: (2011)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts
por: Ardah, Mustafa T., et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers and apolipoprotein E genotype in cerebral amyloid angiopathy. A narrative review
por: Theodorou, Aikaterini, et al.
Publicado: (2021)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Screening for Novel Inhibitors of Amyloid Beta Aggregation and Toxicity as Potential Drugs for Alzheimer’s Disease
por: Sharari, Sanaa, et al.
Publicado: (2023)

Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
por: Ghanem, Simona S., et al.
Publicado: (2021)

Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies
por: Gupta, Vijay, et al.
Publicado: (2020)

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
por: Karampetsou, Mantia, et al.
Publicado: (2017)

RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation
por: Oueslati, Abid, et al.
Publicado: (2014)

KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species
por: Pampalakis, Georgios, et al.
Publicado: (2016)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay
por: Cariulo, Cristina, et al.
Publicado: (2019)

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy
por: Wu, Jia-Zhen, et al.
Publicado: (2019)

Recognizing Atypical Presentations of Alzheimer’s Disease: The Importance of CSF Biomarkers in Clinical Practice
por: Paraskevas, George P., et al.
Publicado: (2022)

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies
por: Foska, Aikaterini, et al.
Publicado: (2022)

Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy
por: Xilouri, Maria, et al.
Publicado: (2009)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
por: Kakuda, Keita, et al.
Publicado: (2019)

Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study
por: Donadio, V., et al.
Publicado: (2018)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Towards a Functional Approach to the Assessment of Daily Life Physical Activity in Children: Are the PAQ-C and Fitbit Flex-2 Technically Adequate?
por: Venetsanou, Fotini, et al.
Publicado: (2020)

From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer’s Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients
por: Tsantzali, Ioanna, et al.
Publicado: (2021)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity
por: Hmila, Issam, et al.
Publicado: (2022)

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
por: Oliveira, Luis M. A., et al.
Publicado: (2021)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid(42) and DJ-1 in Human Cerebrospinal Fluid
por: Kruse, Niels, et al.
Publicado: (2016)

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Identification and Functional Characterization of a Calcium-Sensing Receptor Mutation in an Infant with Familial Hypocalciuric Hypercalcemia
por: Papadopoulou, Anna, et al.
Publicado: (2016)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_31l5p1eg6b1dmrnkm1e2432uic